novo nordisk semaglutide fda The has issued a warning to over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and FDA sends letter to Novo

These delays highlight the structural barriers that can slow adoption in populations with higher rates of comorbidities

Semaglutide injections can be administered regardless of meal timing, but clinical evidence suggests fasting may optimize absorption and GI tolerability

The smooth dialing mechanism and clear dose clicks provide patients with complete confidence during their weekly routine, ensuring an excellent and stress-free care experience

Most semaglutide side effects are mild and temporary, but some can be serious

Interestingly, in the last years glucose lowering agents have been associated with a number of extra-glycemic effects, including cardiovascular benefits, nephroprotection, and weight loss

Passionate about pharmacy advocacy